Mitochondria-Targeted Compounds - SPARC

More documents

Recommendations

Info

Plasma levels of MitoQ in humansfollowing oral administration[MitoQ] (ng/ml)45403530252015MitoQ (1 mg/kg oral)C max = 33.15 ng/mlT max = 1 hourMean ± SD, N = 610500 2 4 6 8 10 12Time (hour)
Human Phase II trials with MitoQ(Antipodean Pharmaceuticals Incwww.antipodeanpharma.com)• Parkinson’s Disease “Protect Trial”– A double-blind, prospective, randomized comparison of 2 doses of MitoQ (40 and 80 mg) andplacebo for the treatment of patients With Parkinson’s Disease– Primary outcome: Unified Parkinson's Disease Rating Scale (UPDRS) score at the final studyvisit compared to baseline– Multi centre (New Zealand and Australia), fully recruited (128 patients), outcome due March2008.• Hepatitis C– Phase II clinical trial of MitoQ to investigate the drug’s efficacy to reduce liver damage inpatients with raised liver enzymes associated with the Hepatitis C virus (HCV).– Auckland, NZ. Started recruiting February 2007
Page 1 and 2: Targeting Antioxidants and RedoxPro
Page 3 and 4: Mitochondria and Oxidative StressOv
Page 10 and 11: Critical questions•ROS-Which?-Whe
Page 12: Mitochondrial ROS metabolism
Page 15 and 16: JBC (2001) 276 4588-4596Uptake of M
Page 17 and 18: Prevention of Lipid Peroxidation by
Page 19 and 20: MitoQ variantsFEBS Letts (2004) 571
Page 21 and 22: JBC (2005) 280 21295 - 21312
Page 23 and 24: Complex III with MitoQ
Page 25 and 26: Steric inhibition is not involved i
Page 28 and 29: JBC (2007) in press
Page 30 and 31: Annu Rev Pharm Tox (2007) 47 629-65
Page 33 and 34: Distribution of TPMP in Mice25TPMP
Page 35 and 36: Protection of mitochondrial functio
Page 37: Pharmaceutical development of MitoQ

Mitochondria-Targeted Compounds - SPARC

Create successful ePaper yourself

Delete template?

Save as template?